Ozelle Unveils Automated Hematology Analyzer at ADLM 2026

In July 2026, Ozelle introduced the O-Cyte 1, which is an automated hematology analyzer, at ADLM 2026 in Anaheim, California. It uses AI and Complete Blood Morphology and is an important milestone for the company’s goals according to the 4th Generation of Hematology Analysis. It integrates morphological intelligence, efficiency, and ease of operation in a compact hematology platform.

Next-generation hematology platforms offer fast-paced, dependable, and significantly automated blood cell analysis. Various laboratories intend to include morphology data in day-to-day processes with good consistency, proper monitoring, and functional efficiency. This is becoming necessary at a time when the workload on the clinical staff is increasing. O-Cyte 1 does not replace conventional laboratory competence but complements it by providing image-based morphology to the automated hematology operations.

It uses AI and Complete Blood Morphology (CBM) to extract structured morphology insights from cell images, which facilitates laboratories in using visual cell data along with hematology results. O-Cyte 1 can perform up to 60 tests per hour as a single unit and up to 360 tests per hour via progressive expansion, which facilitates laboratories to scale capacity as demand increases.

Other than O-Cyte 1, Ozelle also showed its increasing range of clinical hematology products at ADLM 2026, which includes integrated multi-purpose diagnosis tools that provide hematology, immunoassay, and biochemistry tests. The company also demonstrated its compact 7-diff hematology analyzers, which facilitate cell imaging and ease of maintenance.

Impact on the AI Industry

According to Precedence Research, the launch of the O-Cyte 1 is expected to positively impact the AI industry due to the fact that it provides automation in pathological workflows. It helps to build upon the abilities of physicians and not replace them, which will help it to be rapidly adopted in the medical sector. This platform provides the ability to extract insights from cell images, which helps pathologists to use the data alongside their own testing methods to provide more accurate results to the patient.

The increasing number of patients in hospitals due to the growing prevalence of various diseases owing to modern lifestyles has resulted in an increased workload on medical professionals. Automation models will help them ease the burden and allow them to focus more on providing better treatment to the patient. 

Impact on the Artificial Intelligence in Diagnostics Market

The global artificial intelligence in diagnostics market size was estimated at USD 1.94 billion in 2025 and is anticipated to reach around USD 11.82 billion by 2035, expanding at a CAGR of 19.81% from 2026 to 2035.

According to Precedence Research, the introduction of O-Cyte 1 is expected to benefit the artificial intelligence in diagnostics market owing to the fact that it helps clinicians perform faster, more comprehensive, and more accurate analysis of the collected biological samples than they would with just manual testing. The AI algorithms can store a huge amount of historical medical data and use it to provide actionable insights on different formats of data. 

Such systems enable pathologists to quickly perform sample tests and then invest more time in providing an accurate conclusion to the patients about the analytical data in their medical reports. The impact of AI in processing data is expected to increase with time as AI algorithms learn and improve their accuracy as they are exposed to more and more real-world data.

Impact on the Cloud Computing Market

The global cloud computing market size was estimated at USD 912.77 billion in 2025 and is predicted to increase from USD 1,106.28 billion in 2026 to approximately USD 5,946.84 billion by 2035, expanding at a CAGR of 20.61% from 2026 to 2035.

According to Precedence Research, the launch of the O-Cyte 1 is expected to positively impact the cloud computing market. This is because the growing adoption of AI tools in medical workflows will result in the generation of a massive amount of data, which would have to be stored in cloud facilities. 

Hospitals and pathology centers usually do not have dedicated data storage facilities in-house. The processing of data and performing agentic tasks requires a significant amount of computational resources, which the cloud computing facilities offer. This helps medical institutions to automate their routine workflows without a significant upfront capital investment.

About Ozelle

Ozelle is a technology company that provides AI-based solutions to healthcare and veterinary organizations to help them offer better services to their patients. The company was founded in a laboratory in Silicon Valley in 2014 and has scaled in Frankfurt, Germany. It provides AI and IoT-based diagnosis tools that help to extract useful insights from clinical data. The company provides solutions that can be adopted in laboratories, clinics, and decentralized care environments. The company trains its AI algorithms on a huge number of real-world cellular data parameters, which enables it to perform consistently across a wide range of samples.